The patents in contention are numbers 3,109,258, 2,222,710 and 3,178,490, all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis. RSV occurs in epidemics almost every winter. People do not develop life-long ...

This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis. RSV occurs in epidemics almost every winter. People do not develop life-long ...

The animation has been released alongside the schematic design for the redevelopment, and the community is being encouraged to provide feedback at community information sessions taking place in April.

CTV National News: Finding the origin of COVID-19 Allison Bamford has the latest on the new findings from a team of scientists, including a virologist from Sask., into the origins of COVID.